TABLE 2.

Comparison of clinical characteristics between the training and testing cohort.

Variables	Total (n = 3458)	Testing (n = 692)	Training (n = 2766)	p
Age, Median (Q1, Q3)	75 (65, 84)	74 (65, 83)	75 (65, 84)	0.742
wbc, Median (Q1, Q3)	10.8 (7.9, 14.8)	10.8 (7.9, 14.83)	10.75 (7.93, 14.78)	0.999
mchc, Median (Q1, Q3)	33 (31.9, 34)	32.9 (31.9, 33.9)	33 (32, 34)	0.074
mcv, Median (Q1, Q3)	91 (87, 95)	91 (86, 95)	91 (87, 95)	0.104
rdw, Median (Q1, Q3)	14.4 (13.6, 15.6)	14.4 (13.7, 15.7)	14.4 (13.6, 15.5)	0.05
Aniongap, Median (Q1, Q3)	14 (12, 17)	14 (12, 17)	14 (12, 17)	0.804
Bun, Median (Q1, Q3)	21 (15, 29)	21 (16, 31)	21 (15, 29)	0.538
Calcium, Median (Q1, Q3)	8.5 (8.1, 8.9)	8.5 (8.1, 8.9)	8.5 (8.1, 8.9)	0.888
Chloride, Median (Q1, Q3)	104 (99, 108)	104 (99, 108)	104 (99, 108)	0.782
inr, Median (Q1, Q3)	1.3 (1.1, 1.5)	1.3 (1.1, 1.6)	1.3 (1.1, 1.5)	0.308
ptt, Median (Q1, Q3)	31.5 (27.6, 38.2)	31 (27.3, 37.1)	31.6 (27.7, 38.4)	0.168
Npro.BNP, Median (Q1, Q3)	2526.5 (1188.5, 4441)	2580.5 (1176.75, 4479.5)	2490 (1193.25, 4440.5)	0.677
heart.rate, Median (Q1, Q3)	84 (74, 97)	85 (74, 98)	84 (74, 97)	0.454
resp.rate, Median (Q1, Q3)	18 (15, 22)	18 (15, 22)	18 (15, 22)	0.66
SpO2, Median (Q1, Q3)	98 (95, 100)	98.5 (96, 100)	98 (95, 100)	0.339
Glucose, Median (Q1, Q3)	134 (109, 173)	137 (109.75, 175)	134 (109, 172)	0.534
cerebrovascular.disease, n (%)				0.978
0	2912 (84)	582 (84)	2330 (84)
1	546 (16)	110 (16)	436 (16)
Paraplegia, n (%)				1
0	3343 (97)	669 (97)	2674 (97)
1	115 (3)	23 (3)	92 (3)
Aids, n (%)				1
0	3455 (100)	692 (100)	2763 (100)
1	3 (0)	0 (0)	3 (0)
mechvent, n (%)				0.214
0	1247 (36)	235 (34)	1012 (37)
1	2211 (64)	457 (66)	1754 (63)
rrt, n (%)				0.574
0	3424 (99)	687 (99)	2737 (99)
1	34 (1)	5 (1)	29 (1)
Hyperlipidemia, n (%)				0.044
0	1633 (47)	351 (51)	1282 (46)
1	1825 (53)	341 (49)	1484 (54)
Dead, n (%)				0.087
0	2999 (87)	586 (85)	2413 (87)
1	459 (13)	106 (15)	353 (13)